The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

The Life History of 21 Breast Cancers


  • Serena Nik-Zainal
  • Peter Van Loo
  • David C. Wedge
  • Ludmil B. Alexandrov
  • Christopher D. Greenman
  • King Wai Lau
  • Keiran Raine
  • David Jones
  • John Marshall
  • Manasa Ramakrishna
  • Adam Shlien
  • Susanna L. Cooke
  • Jonathan Hinton
  • Andrew Menzies
  • Lucy A. Stebbings
  • Catherine Leroy
  • Mingming Jia
  • Richard Rance
  • Laura J. Mudie
  • Stephen J. Gamble
  • Philip J. Stephens
  • Stuart McLaren
  • Patrick S. Tarpey
  • Elli Papaemmanuil
  • Helen R. Davies
  • Ignacio Varela
  • David J. McBride
  • Graham R. Bignell
  • Kenric Leung
  • Adam P. Butler
  • Jon W. Teague
  • Sancha Martin
  • Goran Joensson
  • Odette Mariani
  • Sandrine Boyault
  • Penelope Miron
  • Aquila Fatima
  • Anita Langerod
  • Samuel A. J. R. Aparicio
  • Andrew Tutt
  • Anieta M. Sieuwerts
  • Åke Borg
  • Gilles Thomas
  • Anne Vincent Salomon
  • Andrea L. Richardson
  • Anne-Lise Borresen-Dale
  • P. Andrew Futreal
  • Michael R. Stratton
  • Peter J. Campbell

Summary, in English

Cancer evolves dynamically as clonal expansions supersede one another driven by shifting selective pressures, mutational processes, and disrupted cancer genes. These processes mark the genome, such that a cancer's life history is encrypted in the somatic mutations present. We developed algorithms to decipher this narrative and applied them to 21 breast cancers. Mutational processes evolve across a cancer's lifespan, with many emerging late but contributing extensive genetic variation. Subclonal diversification is prominent, and most mutations are found in just a fraction of tumor cells. Every tumor has a dominant subclonal lineage, representing more than 50% of tumor cells. Minimal expansion of these subclones occurs until many hundreds to thousands of mutations have accumulated, implying the existence of long-lived, quiescent cell lineages capable of substantial proliferation upon acquisition of enabling genomic changes. Expansion of the dominant subclone to an appreciable mass may therefore represent the final rate-limiting step in a breast cancer's development, triggering diagnosis.


  • Breastcancer-genetics
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publishing year










Document type

Journal article


Cell Press


  • Cancer and Oncology




  • ISSN: 1097-4172